Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone

NCT01458886 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: BI 54903 MD
DRUG: Placebo matching Respimat
DRUG: Placebo matching Respimat
DRUG: BI 54903

Sponsor

Boehringer Ingelheim